417721-36-9

Basic information

• Product Name: 4-chloro-7-Methoxyquinoline-6-carboxaMide
• Synonyms: 4-chloro-7-Methoxyquinoline-6-carboxaMide;4-chloro-7-Methoxy-6-QuinolinecarboxaMide;6-QuinolinecarboxaMide, 4-chloro-7-Methoxy-;Lenvatinib Impurity b;4-Chloro-7-methoxy-quinoline-6-carboxylic acid amide;4-Chloro-7-methoxyquinazoline-6-carboxamide;lenvaint-E
• CAS NO: 417721-36-9
• Molecular Formula: C₁₁H₉ClN₂O₂
• Molecular Weight: 236.65436
• EINECS: -0
• Mol File: 417721-36-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 426.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1.380±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 15.28±0.30(Predicted)
• CAS DataBase Reference: 4-chloro-7-Methoxyquinoline-6-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-7-Methoxyquinoline-6-carboxaMide(417721-36-9)
• EPA Substance Registry System: 4-chloro-7-Methoxyquinoline-6-carboxaMide(417721-36-9)

Safety Data

• Hazardous Substances Data: 417721-36-9(Hazardous Substances Data)

Usage

Description

4-chloro-7-Methoxyquinoline-6-carboxamide is a light yellow powder that serves as a crucial intermediate in the pharmaceutical industry. It is a chemical compound with the potential to be synthesized into various pharmaceutical products, particularly in the development of medications for specific health conditions.

Uses

Used in Pharmaceutical Industry:
4-chloro-7-Methoxyquinoline-6-carboxamide is used as a pharmaceutical intermediate for the synthesis of Lenvatinib. Lenvatinib is a tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, and RET, among others. It is primarily used in the treatment of thyroid cancer and has shown potential in treating other types of cancer as well.
As a pharmaceutical intermediate, 4-chloro-7-Methoxyquinoline-6-carboxamide plays a vital role in the development and production of Lenvatinib, contributing to its effectiveness in combating cancer and improving the quality of life for patients suffering from this disease.

Upstream product

• 67608-58-6 4-cyano-3-hydroxy-aniline 

Downstream Products

• 417716-92-8 lenvatinib 
• 417722-52-2 4-(4-amino-2-methylphenoxy)-7-methoxyquinoline-6-carboxylic acid amide 
• 417721-37-0 6-Carbamoyl-4-(3-fluoro-4-nitrophenoxy)-7-methoxyquinoline 
• 417722-93-1 4?(4?amino?3?chlorophenoxy)?7?methoxyquinoline?6?carboxamide 
• 857890-39-2 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoline-carboxamide methanesulfonate 

Relevant articles and documents

A [...] synthetic method

The invention provides a method of synthesizing [...]. First of all the invention to 4 - cyano - 3 - hydroxy aniline as the starting material, by dimethyl carbonate methylation, after third acid in the oximation reaction at room temperature, the conditions in the PPA shut-ring forms the 6 - cyano - 7 - methoxy - 4 - quinolinone, in thionyl chloride formed under the action of the 6 - cyano - 7 - methoxy - 4 - [...], under acidic conditions [...] cyano hydrolysis synthesis of one of the intermediates 6 - formamido - 7 - methoxy - 4 - chloroquinolin. Then the 4 - hydroxy - 2 chloroaniline with cyanogen bromide at low temperature 4 - hydroxy - 2 - chloro cyaniding amine, the 4 - hydroxy - 2 - chloro cyaniding amine with bearing-displacement generating Reeth reaction synthesis [...] another key intermediate 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea. Finally the two intermediate 6 - formamido - 7 - methoxy - 4 - chloroquinolin and 1 - (2 - chloro - 4 - hydroxy-phenyl) - 3 - ring propyl urea in the alkaline environment for carrying out the alkylation reaction [...]. This scheme has mild reaction conditions, no highly toxic reagent, environmental protection and the like.